pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·1h ago·1 min read
save

Experts suggest emphasizing measles survival rates to boost vaccine trust

Oct 21, 2026·read at STAT ↗Neutral

The United States has reported more than 4,400 measles cases this year, roughly twice the number recorded in 2025. At the same time, vaccination rates have fallen in over 1,600 counties between 2017 and 2024, creating conditions for larger outbreaks.

Public health officials have traditionally highlighted the potential for death from measles in their outreach, but that strategy is meeting resistance from a growing segment of the population.

Communication experts now argue that messages should instead acknowledge what many parents already know-that most children who contract measles recover. By being transparent about the typical outcome, officials hope to appear more credible.

If the approach succeeds, it could improve trust in vaccines and help reverse the decline in coverage, reducing the risk of future outbreaks.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “A counterintuitive way to build trust in measles vaccines and public health”

read at STAT ↗
1,665 words · retrieved 49m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Boundless Bio, Inc.Ultragenyx Pharmaceutical Inc.
topics
Vaccine16Vaccines13Infectious Disease5Immunology2Rare Disease

related stories

  • Oct 9How Abogen went from COVID hype to a $7.8B Novartis dealBioSpace
  • Jun 1Opinion: What should hospitals do when patients demand unvaccinated donor blood?STAT
  • 20h agoEyepoint, Enlivex enact heavy layoffsBioSpace
  • Oct 13BioNTech faces 3rd mRNA setback as head and neck cancer therapy fails to improve survivalBioSpace
  • Sep 14After a brief storm of political headwinds, mRNA is back with strong momentumBioSpace